Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Medical Officer | August 02, 2023 | August 04, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date August 02, 2023 · Filed August 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,440.335 |
Reported balance
After 2023-08-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-08-02 · Sale · Disposed 509 · Balance 52,440.335 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2: Includes 643.335 shares of common stock acquired under the issuer's employee stock purchase plan in June 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
F2: Includes 643.335 shares of common stock acquired under the issuer's employee stock purchase plan in June 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 02, 2023 Filed Aug 4, 2023 20:47 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 509 | $34.88 | $17,751.38 |
DisclosureSEC source: 0001396814-23-000041 · wk-form4_1691182061.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,440.335 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 643.335 shares of common stock acquired under the issuer's employee stock purchase plan in June 2023. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 27,500 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038033 · doc4.xml · derivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,500 Underlying: Common Stock · 27,500 shares Expires 2033-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:45 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 10,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038033 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,306 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2024, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 01:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,857 | $37.87 | $70,315.31 |
DisclosureSEC source: 0001209191-23-035266 · doc4.xml · nonDerivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,356 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 01:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,779 | $38.99 | $69,364.99 |
DisclosureSEC source: 0001209191-23-035266 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,213 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 20:06 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 476 | $55.70 | $26,513.20 |
DisclosureSEC source: 0001209191-22-044560 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,992 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 408 shares of common stock acquired under the issuer's employee stock purchase plan in June 2022. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 24,800 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · derivative · entry 13 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,800 Underlying: Common Stock · 24,800 shares Expires 2032-06-08 F13 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 9,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 11 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,060 F11 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,250 | $0.00 Strike: $34.38 | $0.00 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · derivative · entry 12 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 123 | $63.69 | $7,833.87 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 10 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,160 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.60 to $64.06, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,891 | $62.48 | $118,149.68 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 9 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,283 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.200 to $62.935, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,650 | $61.59 | $224,803.50 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 8 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,174 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.22 to $62.18, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,533 | $60.55 | $213,923.15 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 7 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,824 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.220 to $61.215, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 115 | $63.40 | $7,291.00 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 6 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,357 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.29 to $64.14, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,300 | $62.43 | $81,159.00 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 5 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,472 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.23 to $62.78, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,300 | $61.59 | $141,657.00 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 4 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,772 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.23 to $62.17, inclusive. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,535 | $60.55 | $153,494.25 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 3 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,072 F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.23 to $61.22, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 3 through 10. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 6,250 | $34.38 | $214,843.75 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 23:48 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,099 | $61.37 | $128,824.03 |
DisclosureSEC source: 0001209191-22-035234 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,357 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $48.15 | $0.00 |
DisclosureSEC source: 0001209191-21-063386 · doc4.xml · derivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 21:22 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 10,000 | $48.15 | $481,500.00 |
DisclosureSEC source: 0001209191-21-063386 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $60.79 | $0.00 |
DisclosureSEC source: 0001209191-21-049945 · doc4.xml · derivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-07-20 F3 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on June 20, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 20:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049945 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,456 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on August 1, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 421 shares of common stock acquired under the issuer's employee stock purchase plan in June 2021. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040089 · doc4.xml · derivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040089 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,035 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,276 | $61.04 | $138,920.21 |
DisclosureSEC source: 0001209191-21-038903 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,035 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,750 | $0.00 Strike: $34.38 | $0.00 |
DisclosureSEC source: 0001209191-21-024791 · doc4.xml · derivative · entry 5 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 13,750 shares Expires 2028-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,200 | $72.12 | $86,544.00 |
DisclosureSEC source: 0001209191-21-024791 · doc4.xml · nonDerivative · entry 4 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,311 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $71.80 to $72.48, inclusive. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,661 | $71.09 | $331,350.49 |
DisclosureSEC source: 0001209191-21-024791 · doc4.xml · nonDerivative · entry 3 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,511 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $70.80 to $71.79, inclusive. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 16,363 | $70.36 | $1,151,300.68 |
DisclosureSEC source: 0001209191-21-024791 · doc4.xml · nonDerivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,172 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.80 to $70.79, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 through 4. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 13,750 | $34.38 | $472,656.25 |
DisclosureSEC source: 0001209191-21-024791 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,535 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,000 | $62.00 | $310,000.00 |
DisclosureSEC source: 0001209191-20-058819 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,785 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · balance_after: Includes 548 shares of common stock acquired under the issuer's employee stock purchase plan in June 2020. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036054 · doc4.xml · derivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:36 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036054 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,237 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 23:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 2,500 | $36.50 | $91,250.00 |
DisclosureSEC source: 0001209191-20-018635 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,237 F1 · balance_after: Includes 598 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 33,800 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035141 · doc4.xml · derivative · entry 3 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,800 Underlying: Common Stock · 33,800 shares Expires 2029-06-05 F4 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 21:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035141 · doc4.xml · nonDerivative · entry 2 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,139 F3 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2020, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 21:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 722 | $42.91 | $30,981.02 |
DisclosureSEC source: 0001209191-19-035141 · doc4.xml · nonDerivative · entry 1 WINSTON ROY · CIK 0001751757 · Chief Clinical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,539 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. F2 · balance_after: Includes 761 shares of common stock acquired under the issuer's employee stock purchase plan in December 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.